Sex and gender differences in the treatment of arterial hypertension

References

• Williams B, Mancia G, Spiering W, et al. ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;71:e127–e248.
   PubMed Web of Science ®Google Scholar
• GBD 2019. Risk factors collaborators. global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1223–1249.
   PubMedGoogle Scholar
• Fryar CD, Ostchega Y, Hales CM, et al. Hypertension prevalence and control among adults: United States, 2015-2016. NCHS Data Brief. 2017;(289):1–8.
   Google Scholar
• Wenger NK, Arnold A, Bairey Merz CN, et al. Hypertension across a woman’s life cycle. J Am Coll Cardiol. 2018;71:1797–1813.
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American heart association. Circulation. 2021;143:e254–e743.
   Google Scholar
• NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–980.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395:795–808.
   PubMed Web of Science ®Google Scholar
• Patel SA, Winkel M, Ali MK, et al. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann Intern Med. 2015;163:245–253.
   PubMed Web of Science ®Google Scholar
• Bairey Merz CN, Andersen H, Sprague E, et al. Knowledge, attitudes, and beliefs regarding cardiovascular disease in women: the women’s heart alliance. J Am Coll Cardiol. 2017;70:123–132.
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Oertelt-Prigione S, et al.; EUGenMed Cardiovascular Clinical Study Group. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37(1):24–34.
   Google Scholar
• Gerdts E, Regitz-Zagrosek V. Sex differences in cardiometabolic disorders. Nat Med. 2019;25:1657–1666.
   PubMed Web of Science ®Google Scholar
• Muiesan ML, Salvetti M, Rosei CA, et al. Gender differences in antihypertensive treatment: myths or legends? High Blood Press Cardiovasc Prev. 2016;23:105–113.
   PubMed Web of Science ®Google Scholar
• Gerdts E, de Simone G. Hypertension in women: should there be a sex-specific threshold? Eur Cardiol. 2021;16:e38.
   PubMedGoogle Scholar
• Gerdts E, Sudano I, Brouwers S, et al. Sex differences in arterial hypertension. Eur Heart J. 2022;43(46):4777–4788.
   Google Scholar
• Tamargo J, Caballero R, Delpón E. Pharmacotherapy for hypertension in pregnant patients: special considerations. Expert Opin Pharmacother. 2019;20:963–982.
   PubMed Web of Science ®Google Scholar
• Clayton JA, Tannenbaum C. Reporting sex, gender, or both in clinical research? JAMA. 2016;316:1863–1864.
   PubMed Web of Science ®Google Scholar
• Connelly PJ, Azizi Z, Alipour P, et al. The importance of gender to understand sex differences in cardiovascular disease. Can J Cardiol. 2021;37:699–710.
   PubMed Web of Science ®Google Scholar
• Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75:285–292.
   PubMed Web of Science ®Google Scholar
• Beale AL, Meyer P, Marwick TH, et al. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation. 2018;138:198–205.
   PubMed Web of Science ®Google Scholar
• Ramirez LA, Sullivan JC. Sex differences in hypertension: where we have been and where we are going. Am J Hypertens. 2018;31:1247–1254.
   PubMed Web of Science ®Google Scholar
• Gerdts E, Oikarinen L, Palmieri V, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study. Hypertension. 2002;39:739–743.
   PubMed Web of Science ®Google Scholar
• Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–1562.
   PubMed Web of Science ®Google Scholar
• Lam CSP, Arnott C, Beale AL, et al. Sex differences in heart failure. Eur Heart J. 2019;40:3859–3868c.
   PubMed Web of Science ®Google Scholar
• Dewan P, Rørth R, Jhund PS, et al. Differential impact of heart failure with reduced ejection fraction on men and women. J Am Coll Cardiol. 2019;73:29–40.
   PubMedGoogle Scholar
• Izzo R, Losi M-A, Stabile E, et al. Development of left ventricular hypertrophy in treated hypertensive outpatients: the Campania Salute Network. Hypertension. 2017;69:136–142.
   PubMed Web of Science ®Google Scholar
• de Simone G, Devereux RB, Izzo R, et al. Lack of reduction of left ventricular mass in treated hypertension: the strong heart study. J Am Heart Assoc. 2013;2:e000144.
   PubMedGoogle Scholar
• Mancusi C, Canciello G, Izzo R, et al. Left atrial dilatation: a target organ damage in young to middle-age hypertensive patients. The campania salute network. Int J Cardiol. 2018;265:229–233.
   PubMed Web of Science ®Google Scholar
• Espnes H, Ball J, Løchen M-L, et al. Sex-specific associations between blood pressure and risk of atrial fibrillation subtypes in the tromsø study. J Clin Med. 2021;10:1514.
   PubMedGoogle Scholar
• Nardin C, Maki-Petaja KM, Miles KL, et al. Cardiovascular phenotype of elevated blood pressure differs markedly between young males and females: the enigma study. Hypertension. 2018;72:1277–1284.
   PubMed Web of Science ®Google Scholar
• Martins D, Nelson K, Pan D, et al. The effect of gender on age-related blood pressure changes and the prevalence of isolated systolic hypertension among older adults: data from NHANES III. J Gend Specif Med. 2001;4:10–3, 20.
   PubMedGoogle Scholar
• Coutinho T. Arterial stiffness and its clinical implications in women. Can J Cardiol. 2014;30:756–764.
   PubMed Web of Science ®Google Scholar
• DuPont JJ, Kenney RM, Patel AR, et al. Sex differences in mechanisms of arterial stiffness. Br J Pharmacol. 2019;176:4208–4225.
   PubMedGoogle Scholar
• Bairey Merz CN, Pepine CJ, Shimokawa H, et al. Treatment of coronary microvascular dysfunction. Cardiovasc Res. 2020;116:856–870.
   PubMedGoogle Scholar
• Albrektsen G, Heuch I, Løchen M-L, et al. Risk of incident myocardial infarction by gender: interactions with serum lipids, blood pressure and smoking. The Tromsø Study 1979-2012. Atherosclerosis 2017;261:52–59.
   PubMedGoogle Scholar
• Rexrode K. Sex differences in sex hormones, carotid atherosclerosis, and stroke. Circ Res. 2018;122:17–19.
   PubMedGoogle Scholar
• Singh N, Moody AR, Zhang B, et al. Age-specific sex differences in magnetic resonance imaging-depicted carotid intraplaque hemorrhage. Stroke. 2017;48:2129–2135.
   PubMedGoogle Scholar
• Ieamtairat P, Soontrapa S, Kaewrudee S, et al. Difference in carotid intima-media thickness between pre and postmenopausal women. Menopause. 2019;26:39–44.
   PubMedGoogle Scholar
• Bruno RM, Grassi G, Seravalle G, et al. Age- and sex-specific reference values for media/lumen ratio in small arteries and relationship with risk factors. Hypertension. 2018;71:1193–1200.
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Allison MA, Gomes AS, et al. A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Circulation. 2012;125:1449–1472.
   PubMed Web of Science ®Google Scholar
• Gorgui J, Gorshkov M, Khan N, et al. Hypertension as a risk factor for ischemic stroke in women. Can J Cardiol. 2014;30:774–782.
   PubMed Web of Science ®Google Scholar
• Branyan TE, Sohrabji F. Sex differences in stroke co-morbidities. Exp Neurol. 2020;332:113384.
   PubMedGoogle Scholar
• Leppert MH, Burke JF, Lisabeth LD, et al. Systematic review of sex differences in ischemic strokes among young adults: are young women disproportionately at risk? Stroke. 2022;53:319–327.
   PubMedGoogle Scholar
• Matthews KA, Kuller LH, Chang Y, et al. Premenopausal risk factors for coronary and aortic calcification: a 20-year follow-up in the healthy women study. Prev Med. 2007;45:302–308.
   PubMed Web of Science ®Google Scholar
• Diederichsen A, Lindholt JS, Møller JE, et al. Sex differences in factors associated with progression of aortic valve calcification in the general population. Circ Cardiovasc Imaging. 2022;15:e013165.
   PubMedGoogle Scholar
• Garawi F, Devries K, Thorogood N, et al. Global differences between women and men in the prevalence of obesity: is there an association with gender inequality? Eur J Clin Nutr. 2014;68:1101–1106.
   PubMed Web of Science ®Google Scholar
• Wilsgaard T, Schirmer H, Arnesen E. Impact of body weight on blood pressure with a focus on sex differences: the tromso study, 1986-1995. Arch Intern Med. 2000;160:2847–2853.
   PubMed Web of Science ®Google Scholar
• Palatini P, Mos L, Santonastaso M, et al. Premenopausal women have increased risk of hypertensive target organ damage compared with men of similar age. J Womens Health (Larchmt). 2011;20:1175–1181.
   PubMed Web of Science ®Google Scholar
• Satoh M, Hirose T, Nakayama S, et al. Blood pressure and chronic kidney disease stratified by gender and the use of antihypertensive drugs. J Am Heart Assoc. 2020;9:e015592.
   PubMedGoogle Scholar
• Shen W, Zhang T, Li S, et al. Race and sex differences of long-term blood pressure profiles from childhood and adult hypertension: the bogalusa heart study. Hypertension. 2017;70:66–74.
   PubMed Web of Science ®Google Scholar
• Wills AK, Lawlor DA, Matthews FE, et al. Life course trajectories of systolic blood pressure using longitudinal data from eight UK cohorts. PLoS Med. 2011;8:e1000440.
   PubMed Web of Science ®Google Scholar
• O’Keeffe LM, Simpkin AJ, Tilling K, et al. Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: a prospective cohort study. Atherosclerosis. 2018;278:190–196.
   PubMedGoogle Scholar
• Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396:565–582.
   PubMed Web of Science ®Google Scholar
• Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol. 2018;14:185–201.
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967.
   PubMed Web of Science ®Google Scholar
• Boggia J, Thijs L, Hansen TW, et al. Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension. 2011;57:397–405.
   PubMed Web of Science ®Google Scholar
• Muntner P, Miles MA, Jaeger BC, et al. Blood Pressure control among US adults, 2009 to 2012 through 2017 to 2020. Hypertension. 2022;79:1971–1980.
   PubMedGoogle Scholar
• Osude N, Durazo-Arvizu R, Markossian T, et al. Age and sex disparities in hypertension control: the multi-ethnic study of atherosclerosis (Mesa). Am J Prev Cardiol. 2021;8:100230.
   PubMedGoogle Scholar
• Vynckier P, Ferrannini G, Rydén L, et al. Gender gap in risk factor control of coronary patients far from closing: results from the European society of cardiology EUROASPIRE V registry. Eur J Prev Cardiol. 2022;29:344–351.
   PubMed Web of Science ®Google Scholar
• Oparil S. Women and hypertension: what did we learn from the women’s health initiative? Cardiol Rev. 2006;14:267–275.
   PubMedGoogle Scholar
• Pana TA, Luben RN, Mamas MA, et al. Long term prognostic impact of sex-specific longitudinal changes in blood pressure. The EPIC-Norfolk Prospective Population Cohort Study. Eur J Prev Cardiol. 2022;29:180–191.
   PubMedGoogle Scholar
• Mancia G, Zambon A, Soranna D, et al. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens. 2014;32:1708–1715. discussion 1716.
   PubMed Web of Science ®Google Scholar
• Gupta P, Patel P, Štrauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69:1113–1120.
   PubMed Web of Science ®Google Scholar
• Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124:1124–1140.
   PubMed Web of Science ®Google Scholar
• Pimenta E. Hypertension in women. Hypertens Res. 2012;35:148–152.
   PubMed Web of Science ®Google Scholar
• Wenger NK, Ferdinand KC, Bairey Merz CN, et al. Women, hypertension, and the systolic blood pressure intervention trial. Am J Med. 2016;129:1030–1036.
   PubMedGoogle Scholar
• Wright JT, Williamson JD, et al.; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116.
   PubMed Web of Science ®Google Scholar
• Foy CG, Lovato LC, Vitolins MZ, et al. Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the systolic blood pressure intervention trial. J Hypertens. 2018;36:904–915.
   PubMedGoogle Scholar
• Ji H, Kim A, Ebinger JE, et al. Sex differences in blood pressure trajectories over the life course. JAMA Cardiol. 2020;5:19–26.
   PubMed Web of Science ®Google Scholar
• Ji H, Niiranen TJ, Rader F, et al. Sex differences in blood pressure associations with cardiovascular outcomes. Circulation. 2021;143:761–763.
   PubMed Web of Science ®Google Scholar
• Muiesan ML, Paini A, Aggiusti C, et al. Hypertension and organ damage in women. High Blood Press Cardiovasc Prev. 2018;25:245–252.
   PubMedGoogle Scholar
• Wei Y-C, George NI, Chang C-W, et al. Assessing sex differences in the risk of cardiovascular disease and mortality per increment in systolic blood pressure: a systematic review and meta-analysis of follow-up studies in the United States. PLoS One. 2017;12:e0170218.
   PubMed Web of Science ®Google Scholar
• Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ. 2018;363:k4247.
   PubMedGoogle Scholar
• Han M, Chen Q, Liu L, et al. Stage 1 hypertension by the 2017 American college of cardiology/American heart association hypertension guidelines and risk of cardiovascular disease events: systematic review, meta-analysis, and estimation of population etiologic fraction of prospective cohort studies. J Hypertens. 2020;38:573–578.
   PubMedGoogle Scholar
• Vasan RS, Massaro JM, Wilson PWF, et al. Antecedent blood pressure and risk of cardiovascular disease: the framingham heart study. Circulation. 2002;105:48–53.
   PubMed Web of Science ®Google Scholar
• Kringeland E, Tell GS, Midtbø H, et al. Factors associated with increase in blood pressure and incident hypertension in early midlife: the Hordaland Health Study. Blood Press. 2020;29:267–275.
   PubMed Web of Science ®Google Scholar
• Conen D, Ridker PM, Buring JE, et al. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ. 2007;335:432.
   PubMedGoogle Scholar
• Brunström M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018;178:28–36.
   PubMed Web of Science ®Google Scholar
• Garcia M, Mulvagh SL, Merz CNB, et al. Cardiovascular Disease in Women: clinical Perspectives. Circ Res. 2016;118:1273–1293.
   PubMed Web of Science ®Google Scholar
• Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669–2680.
   PubMed Web of Science ®Google Scholar
• Cífková R, Strilchuk L. Sex differences in hypertension. Do we need a sex-specific guideline? Front Cardiovasc Med. 2022;9:960336.
   PubMedGoogle Scholar
• Reboussin DM, Allen NB, Griswold ME, et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2018;138:e595–e616.
   Google Scholar
• Bots SH, Groepenhoff F, Eikendal ALM, et al. Adverse drug reactions to guideline-recommended heart failure drugs in women: a systematic review of the literature. JACC Heart Fail. 2019;7:258–266.
   PubMedGoogle Scholar
• Okin PM, Gerdts E, Kjeldsen SE, et al. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy. Hypertension. 2008;52:100–106.
   PubMed Web of Science ®Google Scholar
• Kringeland E, Tell GS, Midtbø H, et al. Stage 1 hypertension, sex, and acute coronary syndromes during midlife: the hordaland health study. Eur J Prev Cardiol. 2022;29:147–154.
   PubMed Web of Science ®Google Scholar
• Mosca L, Hammond G, Mochari-Greenberger H, et al. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey. Circulation. 2013;127:1254–1263.
   PubMed Web of Science ®Google Scholar
• Kloner RA, Sowers JR, DiBona GF, et al. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol. 1996;77:713–722.
   PubMed Web of Science ®Google Scholar
• Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Inter Med. 1997;126:761–767.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Warnold I, Hansson L, et al. Influence of gender on prevention of myocardial infarction by antihypertensives and acetylsalicylic acid: the HOT study. J Gend Specif Med. 2000;3:35–38.
   PubMedGoogle Scholar
• ALLHAT officers and coordinators for the ALLHAT collaborative research group. the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981–2997.
   PubMed Web of Science ®Google Scholar
• Oparil S, Davis BR, Cushman WC, et al. Mortality and morbidity during and after antihypertensive and lipid-lowering treatment to prevent heart attack trial: results by sex. Hypertension. 2013;61:977–986.
   PubMed Web of Science ®Google Scholar
• Yamal J-M, Oparil S, Davis BR, et al. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014;8:808–819.
   PubMedGoogle Scholar
• Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592.
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163–2168.
   PubMed Web of Science ®Google Scholar
• Hudson M, Rahme E, Behlouli H, et al. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure–a population study. Eur J Heart Fail. 2007;9:602–609.
   PubMed Web of Science ®Google Scholar
• Os I, Franco V, Kjeldsen SE, et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the losartan intervention for endpoint reduction in hypertension study. Hypertension. 2008;51:1103–1108.
   PubMedGoogle Scholar
• Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428.
   PubMed Web of Science ®Google Scholar
• Saunders E, Cable G, Neutel J. Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study. J Clin Hypertens (Greenwich). 2008;10:27–33.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Böhm M. Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. J Hum Hypertens. 2011;25:354–363.
   PubMedGoogle Scholar
• Matsui K, Kim-Mitsuyama S, Ogawa H, et al. Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study. Hypertens Res. 2014;37:526–532.
   PubMedGoogle Scholar
• Kario K, Hoshide S. Age- and sex-related differences in efficacy with an angiotensin ii receptor blocker and a calcium channel blocker in asian hypertensive patients. J Clin Hypertens (Greenwich). 2016;18:672–678.
   PubMedGoogle Scholar
• Cabaleiro T, Román M, Ochoa D, et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos. 2013;41:224–229.
   PubMed Web of Science ®Google Scholar
• Zapater P, Novalbos J, Gallego-Sandín S, et al. Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers. J Cardiovasc Pharmacol. 2004;43:737–744.
   PubMed Web of Science ®Google Scholar
• Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(Suppl 1):S73–86.
   PubMedGoogle Scholar
• Peeters LEJ, Tjong LK, Rietdijk WJR, et al. Sex differences in spironolactone and the active metabolite canrenone concentrations and adherence. Biomedicines. 2022;10:137.
   PubMedGoogle Scholar
• Tamargo J, Caballero R, Delpón E. Sex-related differences in the pharmacological treatment of heart failure. Pharmacol Ther. 2022;229:107891.
   PubMedGoogle Scholar
• Luzier AB, Killian A, Wilton JH, et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 1999;66:594–601.
   PubMed Web of Science ®Google Scholar
• Walle T, Walle UK, Cowart TD, et al. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther. 1989;46:257–263.
   PubMed Web of Science ®Google Scholar
• Walle T, Byington RP, Furberg CD, et al. Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther. 1985;38:509–518.
   PubMedGoogle Scholar
• Tamargo J, Rosano G, Walther T, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017;3:163–182.
   PubMedGoogle Scholar
• Hendriksen LC, Omes-Smit G, Koch BCP, et al. Sex-based difference in the effect of metoprolol on heart rate and bradycardia in a population-based setting. J Pers Med. 2022;12:870.
   PubMedGoogle Scholar
• Eugene AR. Gender based dosing of metoprolol in the elderly using population pharmacokinetic modeling and simulations. Int J Clin Pharmacol Toxicol. 2016;5:209–215.
   PubMedGoogle Scholar
• Abad-Santos F, Novalbos J, Gálvez-Múgica M-A, et al. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol Res. 2005;51:445–452.
   PubMed Web of Science ®Google Scholar
• Schwartz JB, Capili H, Wainer IW. Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. Clin Pharmacol Ther. 1994;56:368–376.
   PubMedGoogle Scholar
• Sáenz-Campos D, Bayés MC, Martin S, et al. Gender related pharmacokinetics of diltiazem in healthy subjects. Int J Clin Pharmacol Ther. 1995;33:397–400.
   PubMedGoogle Scholar
• Werner U, Werner D, Heinbüchner S, et al. Gender is an important determinant of the disposition of the loop diuretic torasemide. J Clin Pharmacol. 2010;50:160–168.
   PubMedGoogle Scholar
• Ueno K, Sato H. Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs. Hypertens Res. 2012;35:245–250.
   PubMed Web of Science ®Google Scholar
• Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014;171:580–594.
   PubMed Web of Science ®Google Scholar
• Klassen GA, Yeung PF, Barclay KD, et al. Gender differences in exercise and recovery blood pressure responses in normal volunteers given diltiazem. J Clin Pharmacol. 1995;35:1144–1149.
   PubMed Web of Science ®Google Scholar
• Kendall MJ, Quarterman CP, Jack DB, et al. Metoprolol pharmacokinetics and the oral contraceptive pill. Br J Clin Pharmacol. 1982;14:120–122.
   PubMedGoogle Scholar
• Krecic-Shepard ME, Barnas CR, Slimko J, et al. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000;40:219–230.
   PubMed Web of Science ®Google Scholar
• Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos. 2006;27:329–334.
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545–1553.
   PubMed Web of Science ®Google Scholar
• Fletcher A, Beevers DG, Bulpitt C, et al. Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988;2:219–227.
   Google Scholar
• Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative. Hypertension. 2000;36:780–789.
   PubMed Web of Science ®Google Scholar
• Fan X, Han Y, Sun K, et al. Sex differences in blood pressure response to antihypertensive therapy in Chinese patients with hypertension. Ann Pharmacother. 2008;42:1772–1781.
   PubMedGoogle Scholar
• Chapman AB, Schwartz GL, Boerwinkle E, et al. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002;61:1047–1055.
   PubMed Web of Science ®Google Scholar
• Gueyffier F, Subtil F, Bejan-Angoulvant T, et al. Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial. J Hum Hypertens. 2015;29:22–27.
   PubMedGoogle Scholar
• Musini VM, Nazer M, Bassett K, et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;(5):CD003824.
   PubMed Web of Science ®Google Scholar
• Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816–1826.
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA. 2004;292:2849–2859.
   PubMed Web of Science ®Google Scholar
• Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53:672–677.
   PubMed Web of Science ®Google Scholar
• Komukai K, Mochizuki S, Yoshimura M. Gender and the renin-angiotensin-aldosterone system. Fundam Clin Pharmacol. 2010;24:687–698.
   PubMed Web of Science ®Google Scholar
• Hilliard LM, Sampson AK, Brown RD, et al. The “his and hers” of the renin-angiotensin system. Curr Hypertens Rep. 2013;15:71–79.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Agarwall NR, Tamargo N. Sex differences in cardiac diseases. Cambridge: USA: Elsevier; 2021.
   Google Scholar
• Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. J Biomed Biotechnol. 2011;2011:187103.
   PubMedGoogle Scholar
• Rabi DM, Khan N, Vallee M, et al. Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. Can J Cardiol. 2008;24:491–496.
   PubMedGoogle Scholar
• Clemmer JS, Faulkner JL, Mullen AJ, et al. Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females. Biol Sex Differ. 2019;10:24.
   PubMedGoogle Scholar
• Thoenes M, Neuberger H-R, Volpe M, et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24:336–344.
   PubMed Web of Science ®Google Scholar
• Ljungman C, Kahan T, Schiöler L, et al. Gender differences in antihypertensive drug treatment: results from the Swedish Primary Care Cardiovascular Database (SPCCD). J Am Soc Hypertens. 2014;8:882–890.
   PubMed Web of Science ®Google Scholar
• Keyhani S, Scobie JV, Hebert PL, et al. Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension. 2008;51:1149–1155.
   PubMed Web of Science ®Google Scholar
• Wallentin F, Wettermark B, Kahan T. Drug treatment of hypertension in Sweden in relation to sex, age, and comorbidity. J Clin Hypertens (Greenwich). 2018;20:106–114.
   PubMed Web of Science ®Google Scholar
• Cadeddu C, Franconi F, Cassisa L, et al. Arterial hypertension in the female world: pathophysiology and therapy. J Cardiovasc Med (Hagerstown). 2016;17:229–236.
   PubMedGoogle Scholar
• Muiesan ML, Ambrosioni E, Costa FV, et al. Sex differences in hypertension-related renal and cardiovascular diseases in Italy: the I-DEMAND study. J Hypertens. 2012;30:2378–2386.
   PubMedGoogle Scholar
• Zhao M, Woodward M, Vaartjes I, et al. Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9:e014742.
   PubMed Web of Science ®Google Scholar
• Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534–2544.
   PubMed Web of Science ®Google Scholar
• Pechère-Bertschi A, Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens. 2004;17:994–1001.
   PubMed Web of Science ®Google Scholar
• Qi H, Liu Z, Cao H, et al. Comparative efficacy of antihypertensive agents in salt-sensitive hypertensive patients: a network meta-analysis. Am J Hypertens. 2018;31:835–846.
   PubMedGoogle Scholar
• Puttnam R, Davis BR, Pressel SL, et al. Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial. JAMA Intern Med. 2017;177:67–76.
   PubMedGoogle Scholar
• Bolland MJ, Ames RW, Horne AM, et al. The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int. 2007;18:479–486.
   PubMed Web of Science ®Google Scholar
• Schoofs MWCJ, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for Hip fracture. Ann Intern Med. 2003;139:476–482.
   PubMedGoogle Scholar
• Kalibala J, Pechère-Bertschi A, Desmeules J. Gender differences in cardiovascular pharmacotherapy-the example of hypertension: a mini review. Front Pharmacol. 2020;11:564.
   PubMedGoogle Scholar
• Rydberg DM, Mejyr S, Loikas D, et al. Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. Eur J Clin Pharmacol. 2018;74:1165–1173.
   PubMed Web of Science ®Google Scholar
• Bots SH, Schreuder MM, JE RVL, et al. Sex differences in reported adverse drug reactions to angiotensin-converting enzyme inhibitors. JAMA Network Open. 2022;5:e228224.
   PubMedGoogle Scholar
• Yu Y, Chen J, Li D, et al. Systematic analysis of adverse event reports for sex differences in adverse drug events. Sci Rep. 2016;6:24955.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Hasdemir C, Laver D, et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2011;4:128–135.
   PubMed Web of Science ®Google Scholar
• Rodenburg EM, Stricker BHC, Visser LE. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. Br J Clin Pharmacol. 2011;71:95–104.
   PubMed Web of Science ®Google Scholar
• Igho Pemu P, Ofili E. Hypertension in women: part I. J Clin Hypertens (Greenwich). 2008;10:406–410.
   PubMedGoogle Scholar
• Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens. 2001;14:978–979.
   PubMed Web of Science ®Google Scholar
• Sato A, Fukuda S. A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. Clin Exp Hypertens. 2015;37:563–568.
   PubMed Web of Science ®Google Scholar
• Yılmaz İ. Angiotensin-converting enzyme inhibitors induce cough. Turk Thorac J. 2019;20:36–42.
   PubMedGoogle Scholar
• Thürmann PA, Haack S, Werner U, et al. Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin Pharmacol Ther. 2006;80:551–553.
   PubMedGoogle Scholar
• Manteuffel M, Williams S, Chen W, et al. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt). 2014;23:112–119.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Kjeldsen KP, Delpón E, et al. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European society of cardiology working group on cardiovascular pharmacotherapy. Eur Heart J Cardiovasc Pharmacother. 2022;8(4):406–419.
   Google Scholar
• Biffi A, Rea F, Iannaccone T, et al. Sex differences in the adherence of antihypertensive drugs: a systematic review with meta-analyses. BMJ Open. 2020;10:e036418.
   PubMedGoogle Scholar
• Kim S, Shin DW, Yun JM, et al. Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension. 2016;67:506–512.
   PubMed Web of Science ®Google Scholar
• Gebreyohannes EA, Bhagavathula AS, Abebe TB, et al. Adverse effects and non-adherence to antihypertensive medications in University of gondar comprehensive specialized hospital. Clin Hypertens. 2019;25:1.
   PubMedGoogle Scholar
• Miller JA, Cherney DZ, Duncan JA, et al. Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol. 2006;17:2554–2560.
   PubMed Web of Science ®Google Scholar
• Santema BT, Ouwerkerk W, Tromp J, et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet. 2019;394:1254–1263.
   PubMedGoogle Scholar
• Griffin BL, Bolch CA, Bourjeily G, et al. Hypertension: are current guidelines inclusive of sex and gender? J Womens Health (Larchmt). 2022;31:1391–1396.
   PubMed Web of Science ®Google Scholar
• Engberding N, Wenger NK. Management of hypertension in women. Hypertens Res. 2012;35:251–260.
   PubMedGoogle Scholar
• Clayton JA, Gaugh MD. Sex as a biological variable in cardiovascular diseases: JACC focus seminar 1/7. J Am Coll Cardiol. 2022;79:1388–1397.
   PubMedGoogle Scholar
• Madsen TE, Howard G, Kleindorfer DO, et al. Sex differences in hypertension and stroke risk in the REGARDS study: a longitudinal cohort study. Hypertension. 2019;74:749–755.
   PubMedGoogle Scholar
• Gu Q, Burt VL, Paulose-Ram R, et al. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the national health and nutrition examination survey 1999-2004. Am J Hypertens. 2008;21:789–798.
   PubMed Web of Science ®Google Scholar
• Klungel OH, de Boer A, Paes AH, et al. Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. J Hypertens. 1997;15:591–600.
   PubMedGoogle Scholar
• Sharashova E, Wilsgaard T, Ball J, et al. Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Tromsø Study. Eur Heart J. 2020;41:1554–1562.
   PubMedGoogle Scholar
• Heidari S, Babor TF, De Castro P, et al. Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev. 2016;1:2.
   PubMedGoogle Scholar
• White J, Tannenbaum C, Klinge I, et al. The integration of sex and gender considerations into biomedical research: lessons from international funding agencies. J Clin Endocrinol Metab. 2021;106:3034–3048.
   PubMed Web of Science ®Google Scholar
• Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health. 2022;23:S1–S259.
   PubMedGoogle Scholar
• Caceres BA, Streed CG, Corliss HL, et al. Assessing and addressing cardiovascular health in LGBTQ adults: a scientific statement from the American heart association. Circulation. 2020;142:e321–e332.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin FJ, Kuzior A, Hernandez-Lazaro A, et al. Incidence of hypertension in young transgender people after a 5-year follow-up: association with gender-affirming hormonal therapy. Hypertens Res. 2023;46:219–225.
   PubMedGoogle Scholar
• Irwig MS. Hypertension in transgender individuals. J Hum Hypertens. 2022. 10.1038/s41371-022-00721-w
   PubMedGoogle Scholar